Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive

In This Article:

For Immediate Release

Chicago, IL – November 19, 2024 – Stocks in this week’s article are Rigel Pharmaceuticals RIGL, Synchrony Financial SYF, SkyWest, Inc. SKYW, Allient Inc. ALNT and Rush Street Interactive RSI.

5 Relative Price Strength Options Available to Investors

U.S. markets are grappling with uncertainty as a hawkish tone from Fed Chairman Jerome Powell on rate cuts and President-elect Donald Trump’s nomination of a vaccine skeptic to lead the Department of Health and Human Services weigh on sentiment. With post-election rallies fading, investors are turning cautious. In such volatility, a relative price strength strategy — focusing on stocks outperforming their peers — offers a resilient approach to identifying winning investments while minimizing risks in unpredictable markets.

At this stage, investors would be wise to consider stocks like Rigel Pharmaceuticals, Synchrony Financial, SkyWest, Inc., Allient Inc. and Rush Street Interactive based on their relative price strength.

Relative Price Strength Strategy

Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. But these are also essential for determining whether a stock’s price performance is better than its peers or the industry average.

If a stock’s performance is lacking that of the broader groups, despite impressive earnings growth or valuation multiples, then something must be wrong.

It’s always advisable to stay away from these stocks and bet on those that are outperforming their respective industry or benchmark. This is because betting on a winner always proves to be lucrative.

Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals indicate room for growth and are the best ways to go about this strategy.

Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.

Rigel Pharmaceuticals: It is a clinical-stage company dedicated to discovering and developing innovative small-molecule drugs. RIGL’s focus spans inflammatory diseases, cancer, and viral infections. The Zacks Consensus Estimate for 2024 earnings of Rigel Pharmaceuticals indicates 112.1% growth. Headquartered in South San Francisco, CA, RIGL has a VGM Score of A.